S&P 500   4,277.67 (-0.25%)
DOW   33,371.75 (-0.18%)
QQQ   359.52 (-0.48%)
AAPL   173.22 (-0.31%)
MSFT   320.20 (-0.50%)
META   305.25 (-0.51%)
GOOGL   133.50 (-0.50%)
AMZN   127.86 (-1.24%)
TSLA   247.31 (-1.71%)
NVDA   448.33 (+0.11%)
NIO   8.60 (-2.16%)
BABA   84.46 (-2.39%)
AMD   102.42 (-0.82%)
T   14.64 (-0.20%)
F   12.11 (-1.62%)
MU   68.30 (+0.50%)
CGC   0.70 (-4.55%)
GE   109.24 (+0.41%)
DIS   80.88 (-0.97%)
AMC   8.03 (-1.47%)
PFE   33.72 (-0.65%)
PYPL   57.94 (-1.06%)
NFLX   377.60 (-0.72%)
S&P 500   4,277.67 (-0.25%)
DOW   33,371.75 (-0.18%)
QQQ   359.52 (-0.48%)
AAPL   173.22 (-0.31%)
MSFT   320.20 (-0.50%)
META   305.25 (-0.51%)
GOOGL   133.50 (-0.50%)
AMZN   127.86 (-1.24%)
TSLA   247.31 (-1.71%)
NVDA   448.33 (+0.11%)
NIO   8.60 (-2.16%)
BABA   84.46 (-2.39%)
AMD   102.42 (-0.82%)
T   14.64 (-0.20%)
F   12.11 (-1.62%)
MU   68.30 (+0.50%)
CGC   0.70 (-4.55%)
GE   109.24 (+0.41%)
DIS   80.88 (-0.97%)
AMC   8.03 (-1.47%)
PFE   33.72 (-0.65%)
PYPL   57.94 (-1.06%)
NFLX   377.60 (-0.72%)
S&P 500   4,277.67 (-0.25%)
DOW   33,371.75 (-0.18%)
QQQ   359.52 (-0.48%)
AAPL   173.22 (-0.31%)
MSFT   320.20 (-0.50%)
META   305.25 (-0.51%)
GOOGL   133.50 (-0.50%)
AMZN   127.86 (-1.24%)
TSLA   247.31 (-1.71%)
NVDA   448.33 (+0.11%)
NIO   8.60 (-2.16%)
BABA   84.46 (-2.39%)
AMD   102.42 (-0.82%)
T   14.64 (-0.20%)
F   12.11 (-1.62%)
MU   68.30 (+0.50%)
CGC   0.70 (-4.55%)
GE   109.24 (+0.41%)
DIS   80.88 (-0.97%)
AMC   8.03 (-1.47%)
PFE   33.72 (-0.65%)
PYPL   57.94 (-1.06%)
NFLX   377.60 (-0.72%)
S&P 500   4,277.67 (-0.25%)
DOW   33,371.75 (-0.18%)
QQQ   359.52 (-0.48%)
AAPL   173.22 (-0.31%)
MSFT   320.20 (-0.50%)
META   305.25 (-0.51%)
GOOGL   133.50 (-0.50%)
AMZN   127.86 (-1.24%)
TSLA   247.31 (-1.71%)
NVDA   448.33 (+0.11%)
NIO   8.60 (-2.16%)
BABA   84.46 (-2.39%)
AMD   102.42 (-0.82%)
T   14.64 (-0.20%)
F   12.11 (-1.62%)
MU   68.30 (+0.50%)
CGC   0.70 (-4.55%)
GE   109.24 (+0.41%)
DIS   80.88 (-0.97%)
AMC   8.03 (-1.47%)
PFE   33.72 (-0.65%)
PYPL   57.94 (-1.06%)
NFLX   377.60 (-0.72%)
NASDAQ:KPRX

Kiora Pharmaceuticals (KPRX) News Today

$0.57
-0.02 (-2.54%)
(As of 09:41 AM ET)
Compare
Today's Range
$0.58
$0.60
50-Day Range
$0.48
$0.63
52-Week Range
$0.46
$10.39
Volume
153,643 shs
Average Volume
678,803 shs
Market Capitalization
$4.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$46.00
SourceHeadline
finance.yahoo.com logoKiora Pharmaceuticals Receives Investigational New Drug Application Approval to Expand Phase 1b Study of KIO-301 in Inherited Retinal Diseases; To Enroll Patients with Choroideremia and Additional Patients with Late-Stage Retinitis Pigmentosa
finance.yahoo.com - October 3 at 9:41 AM
finance.yahoo.com logoKiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman; Succeeds Paul Chaney Who is Retiring After Serving 17 Years
finance.yahoo.com - September 21 at 8:05 AM
finance.yahoo.com logoKiora Pharmaceuticals Completes Last Patient, Last Visit in Phase 1B Trial of KIO-301 in Patients with Retinitis Pigmentosa
finance.yahoo.com - September 18 at 8:35 AM
finance.yahoo.com logoKiora Pharmaceuticals to Present Topline Results from the ABACUS Study at American Academy Ophthalmology (AAO); Phase 1b Study Evaluating KIO-301 in Retinitis Pigmentosa
finance.yahoo.com - September 14 at 10:02 AM
finance.yahoo.com logoKiora Pharmaceuticals Adjourns Special Meeting of Stockholders to September 27
finance.yahoo.com - September 1 at 9:40 AM
finance.yahoo.com logoKiora Pharmaceuticals and the Choroideremia Research Foundation to Host Webinar on the Development of Molecular Photoswitches for Inherited Retinal Diseases
finance.yahoo.com - August 29 at 5:13 PM
finance.yahoo.com logoIs Kiora Pharmaceuticals Significantly Undervalued? A Comprehensive Valuation Analysis
finance.yahoo.com - August 24 at 1:09 PM
marketwatch.com logoKiora Pharmaceuticals Shares Up 18% on Patents Covering Ocular Delivery of Molecules
marketwatch.com - August 23 at 3:20 PM
markets.businessinsider.com logoWhy Is Kiora Pharmaceuticals (KPRX) Stock Up 11% Today?
markets.businessinsider.com - August 23 at 10:14 AM
finance.yahoo.com logoKiora Pharmaceuticals Granted U.S. and European Patents for Local Ocular Delivery of the KIO-100 Family of Compounds; New IP Specifically Includes Treatment of Posterior Non-Infectious Uveitis
finance.yahoo.com - August 23 at 10:14 AM
finance.yahoo.com logoKiora Pharmaceuticals Taps B2i Digital to Deploy Data-Driven Investor Awareness Program
finance.yahoo.com - August 22 at 5:34 PM
finance.yahoo.com logoKiora Pharmaceuticals Webcasts Its Investor Presentation from the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
finance.yahoo.com - August 16 at 8:46 AM
finance.yahoo.com logoKiora Pharmaceuticals Announces Q2 2023 Earnings and Business Update, Highlighting Pipeline Updates and Clinical Development Progress
finance.yahoo.com - August 8 at 11:07 AM
finance.yahoo.com logoKiora Pharmaceuticals, Inc. and Choroideremia Research Foundation Partner to Advance Novel Choroideremia Treatment
finance.yahoo.com - August 3 at 10:12 AM
finance.yahoo.com logoBiotech Leader Carmine Stengone Joins Kiora Pharmaceuticals' Board of Directors
finance.yahoo.com - August 1 at 6:35 PM
investorplace.com logoWhy Is Kiora Pharmaceuticals (KPRX) Stock Down 7% Today?
investorplace.com - July 21 at 9:08 AM
finanznachrichten.de logoKiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Receives $1.2 Million in Research Tax Credits to Advance the Treatment of Ophthalmic Disease
finanznachrichten.de - July 5 at 8:54 AM
finance.yahoo.com logoKiora Pharmaceuticals Receives $1.2 Million in Research Tax Credits to Advance the Treatment of Ophthalmic Disease
finance.yahoo.com - July 5 at 8:54 AM
marketwatch.com logo8-K: KIORA PHARMACEUTICALS INC
marketwatch.com - June 22 at 6:32 PM
finance.yahoo.com logoLife Science Investor Forum Agenda Announced for June 22nd
finance.yahoo.com - June 20 at 11:23 AM
finanznachrichten.de logoKiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201
finanznachrichten.de - June 15 at 7:43 AM
finance.yahoo.com logoKiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201
finance.yahoo.com - June 15 at 7:43 AM
finance.yahoo.com logoKiora Pharmaceuticals to Present at Upcoming Investor Conferences
finance.yahoo.com - June 14 at 10:07 AM
finance.yahoo.com logoKiora Pharmaceuticals Announces Closing of $6.3 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
finance.yahoo.com - June 6 at 7:32 PM
baystreet.ca logoKiora Heralds Public Offering
baystreet.ca - June 2 at 12:36 PM
investorplace.com logoWhy Is Kiora Pharmaceuticals (KPRX) Stock Down 49% Today?
investorplace.com - June 2 at 10:09 AM
msn.com logoRecap: Kiora Pharmaceuticals Q1 Earnings
msn.com - May 9 at 3:03 PM
finance.yahoo.com logoKiora Pharmaceuticals Reports First Quarter Results; Positive Clinical Data Driving Significant Progress Advancing Pipeline of Eye Disease Treatments
finance.yahoo.com - May 9 at 10:02 AM
finance.yahoo.com logoKiora Pharmaceuticals Presents Encore Imaging Results of KIO-301 for Retinitis Pigmentosa at ASNR 2023 Meeting
finance.yahoo.com - May 1 at 7:50 AM
finance.yahoo.com logoKiora's Investigational Treatment for Retinitis Pigmentosa, KIO-301, Demonstrates Visual Function Restoration in Patients Who Are Blind
finance.yahoo.com - April 27 at 6:43 PM
finance.yahoo.com logoKiora Pharmaceuticals' KIO-201 Heals Wounds in Phase 2 Trial of Patients with Persistent Corneal Epithelial Defects
finance.yahoo.com - April 26 at 10:14 AM
finanznachrichten.de logoKiora Pharmaceuticals, Inc.: Inherited Retinal Disease Expert, Mark Pennesi, M.D., Ph.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board
finanznachrichten.de - April 21 at 10:51 AM
finance.yahoo.com logoInherited Retinal Disease Expert, Mark Pennesi, M.D., Ph.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board
finance.yahoo.com - April 21 at 10:51 AM
finance.yahoo.com logoKiora Pharmaceuticals Initiates Phase 2 Trial of KIO-101 for the Treatment of Ocular Presentation of Autoimmune Diseases
finance.yahoo.com - April 17 at 9:26 AM
finance.yahoo.com logoKiora Announces the Acceptance of Late-Breaking Abstract on Phase 1b Study of KIO-301 in Retinitis Pigmentosa at The American Society of Neuroradiology 2023 Meeting
finance.yahoo.com - March 30 at 10:02 AM
markets.businessinsider.com logoAnalyst Ratings for Kiora Pharmaceuticals
markets.businessinsider.com - March 24 at 7:19 PM
markets.businessinsider.com logoMaxim Group Reaffirms Their Buy Rating on Kiora Pharmaceuticals (KPRX)
markets.businessinsider.com - March 11 at 4:09 PM
finance.yahoo.com logoKiora Pharmaceuticals Announces the Acceptance of Three Abstracts at the 2023 ARVO Annual Meeting
finance.yahoo.com - March 10 at 7:51 AM
benzinga.com logoKiora Pharmaceuticals Director Awarded $31K Worth of Stock Options
benzinga.com - March 8 at 7:10 PM
markets.businessinsider.com logoAnalysts Offer Insights on Healthcare Companies: Tempest Therapeutics (TPST), Kiora Pharmaceuticals (KPRX) and Indaptus Therapeutics (INDP)
markets.businessinsider.com - February 8 at 9:37 AM
marketwatch.com logoKiora Pharmaceuticals Soars 43% After IND Application Approval for KIO-101
marketwatch.com - February 7 at 1:13 PM
msn.com logoKiora Soars on IND Approval for KIO-101 Eye Drops
msn.com - February 7 at 1:13 PM
marketbeat.com logo
marketbeat.com - February 7 at 9:51 AM
marketwatch.com logoKiora Pharma Shares Rise 55% After IND Application Approval for HIO-101
marketwatch.com - February 7 at 8:13 AM
finance.yahoo.com logoKiora Pharmaceuticals Receives Investigational New Drug Approval for Phase 2 Study of KIO-101 for Treatment of Ocular Presentation of Autoimmune Diseases
finance.yahoo.com - February 7 at 8:12 AM
finance.yahoo.com logoKiora’s stock rallies as eye drop treatment moves into mid-stage clinical trial
finance.yahoo.com - February 7 at 8:12 AM
finance.yahoo.com logoKiora Pharmaceuticals Enters into Two Equity Purchase Agreements with Lincoln Park Capital
finance.yahoo.com - February 3 at 9:26 AM
finance.yahoo.com logoKiora Pharmaceuticals Highlights Anticipated Clinical and Corporate Milestones for 2023; Webcast Now Available on Company Website
finance.yahoo.com - January 9 at 7:30 AM
marketbeat.com logo
marketbeat.com - January 3 at 1:31 PM
marketbeat.com logo
marketbeat.com - January 3 at 1:15 PM
Get Kiora Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for KPRX and its competitors with MarketBeat's FREE daily newsletter.



KPRX Media Mentions By Week

KPRX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

KPRX
News Sentiment

1.44

0.70

Average
Medical
News Sentiment

KPRX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

KPRX Articles
This Week

3

1

KPRX Articles
Average Week

Get Kiora Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for KPRX and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:KPRX) was last updated on 10/3/2023 by MarketBeat.com Staff

My Account -